Tahoe Therapeutics, a biotech startup co-founded by Kevin Shokat, Nima Alidoust, Johnny Yu, and Hani Goodarzi, is making significant strides in the field of biology by digitally simulating living cells. The company recently released Tahoe-100M, a dataset containing 100 million datapoints that showcase how different cancer cells respond to various molecules. This valuable information, known as perturbations, is essential for training AI models to predict how cells will react to different substances accurately.
Using its innovative Mosaic platform, Tahoe can combine cells from various patients and organs to create comprehensive single-cell atlases. This approach allows for the generation of massive datasets needed to train virtual cell models, setting Tahoe apart from other companies in the AI drug discovery space. The company’s ability to quickly scale data production is a key factor in its success and future goals of developing virtual cell models for finding new treatments for cancer and other diseases.
Tahoe recently secured $30 million in new funding, led by Amplify Partners, bringing its total funding to $42 million and valuation to $120 million. This investment will support the company’s mission to build a dataset with over a billion single-cell datapoints to power its virtual cell models. With its proprietary data and models, Tahoe is accelerating the development of new medicines to combat cancer, with a drug candidate already in the works for testing on humans.
In addition to its internal research efforts, Tahoe collaborates with research organizations like Arc Institute, which used Tahoe-100M as part of its training data for the open-source virtual cell model, State. This collaboration resulted in a model with twice the accuracy of other AI models, demonstrating the impact of Tahoe’s data on advancing biological research.
The journey of Tahoe Therapeutics began with co-founders Goodarzi, Alidoust, Yu, and Shokat coming together to pursue the vision of building virtual cell models. Their combined expertise and dedication to collecting large-scale data have positioned Tahoe as a leader in AI-driven drug discovery. The company’s commitment to generating more data for AI models and proving the effectiveness of its technology reflects a bright future in the field of biology.
As Tahoe continues to innovate and expand its capabilities, it aims to collaborate with pharmaceutical companies or AI firms to share its data and expertise. This strategic partnership will not only drive revenue for Tahoe but also contribute to the advancement of drug discovery and development. With a focus on building a better future in biology, Tahoe Therapeutics is at the forefront of revolutionizing how we approach medical research and treatment.
